.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,045,426

« Back to Dashboard

Details for Patent: 9,045,426

Title:Method for producing 1,2-dihydropyridine-2-one compound
Abstract: The present inventions provide a method for commercially producing a 1,2 -dihydropyridine-2-one compound represented by the following formula (III-a) ##STR00001## wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2 -dihydropyridin-2-one and production processes therefore.
Inventor(s): Arimoto; Itaru (Tokyo, JP), Nagato; Satoshi (Tokyo, JP), Sugaya; Yukiko (Tsukuba, JP), Urawa; Yoshio (Kamisu, JP), Ito; Koichi (Tsukuba, JP), Naka; Hiroyuki (Kamisu, JP), Omae; Takao (Tsukuba, JP), Kayano; Akio (Kamisu, JP), Nishiura; Katsutoshi (Kamisu, JP)
Assignee: EISAI R&D MANAGEMENT CO., LTD. (Tokyo, JP)
Filing Date:Jan 27, 2014
Application Number:14/165,365
Claims:1. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 10.3.degree. in a powder X-ray diffraction.

2. The crystal according to claim 1 further having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 19.1.degree. in a powder X-ray diffraction.

3. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having peaks at chemical shifts of around 149.0 ppm and around 125.6 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

4. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 16.7.degree. in a powder X-ray diffraction.

5. The crystal according to claim 4 further having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 12.9.degree. and 24.9.degree. in a powder X-ray diffraction.

6. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having an absorption peak at a wavenumber of 1658.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

7. The crystal according to claim 6 further having an absorption peak at a wavenumber of 501.+-.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

8. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having peaks at chemical shifts of around 145.9 ppm and around 137.7 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

9. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 23.7.degree. and 25.0.degree. in a powder X-ray diffraction.

10. The crystal according to claim 6 further having diffraction peaks at diffraction angles (2.theta..+-.0.2.degree.) of 5.7.degree. and 9.5.degree. in a powder X-ray diffraction.

11. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 10.3.degree., 14.2.degree. and 19.1.degree. in a powder X-ray diffraction.

12. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 7.8.degree., 9.5.degree., 10.3.degree., 14.2.degree., 15.1.degree., 16.1.degree., 19.1.degree. and 20.5.degree. in a powder X-ray diffraction.

13. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having peaks at chemical shifts of around 160.0 ppm, 152.8 ppm, 152.0 ppm, 149.0 ppm, 140.5 ppm, 137.0 ppm, 134.7 ppm, 133.4 ppm, 131.0 ppm, 129.5 ppm, 128.2 ppm, 127.0 ppm, 125.6 ppm, 120.3 ppm, 118.2 ppm, 114.6 ppm and 108.2 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

14. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 12.9.degree., 16.7.degree. and 24.9.degree. in a powder X-ray diffraction.

15. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 8.0.degree., 9.2.degree., 10.0.degree., 12.9.degree., 16.7.degree., 18.4.degree., 18.8.degree., 20.7.degree. and 24.9.degree. in a powder X-ray diffraction.

16. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having peaks at chemical shifts of around 159.7 ppm, 151.2 ppm, 145.9 ppm, 139.9 ppm, 137.7 ppm, 134.9 ppm, 132.8 ppm, 131.7 ppm, 130.1 ppm, 129.0 ppm, 128.2 ppm, 127.3 ppm, 126.8 ppm, 125.8 ppm, 121.1 ppm, 120.6 ppm, 119.1 ppm, 114.2 ppm and 109.4 ppm in a .sup.13C Solid State Nuclear Magnetic Resonance spectrum.

17. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having an absorption peak at a wavenumber of 3447.1.+-.0.1 cm.sup.-1, 3066.3.+-.0.1 cm.sup.-1, 2221.6.+-.0.1 cm.sup.-1, 1657.5.+-.0.1 cm.sup.-1, 1585.2.+-.0.1 cm.sup.-1, 1476.2.+-.0.1 cm.sup.-1 and 785.9.+-.0.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

18. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having an absorption peak at a wavenumber of 3447.1.+-.0.1 cm.sup.-1, 3066.3.+-.0.1 cm.sup.-1, 2221.6.+-.0.1 cm.sup.-1, 1657.5.+-.0.1 cm.sup.-1, 1619.0.+-.0.1 cm.sup.-1, 1585.2.+-.0.1 cm.sup.-1, 1565.9.+-.0.1 cm.sup.-1, 1549.5.+-.0.1 cm.sup.-1, 1476.2.+-.0.1 cm.sup.-1, 1434.8.+-.0.1 cm.sup.-1, 1368.3.+-.0.1 cm.sup.-1, 1318.1.+-.0.1 cm.sup.-1, 1266.0.+-.0.1 cm.sup.-1, 1247.7.+-.0.1 cm.sup.-1, 1157.1.+-.0.1 cm.sup.-1, 1135.9.+-.0.1 cm.sup.-1, 1097.3.+-.0.1 cm.sup.-1, 933.4.+-.0.1 cm.sup.-1, 896.7.+-.0.1 cm.sup.-1, 879.4.+-.0.1 cm.sup.-1, 785.9.+-.0.1 cm.sup.-1, 753.1.+-.0.1 cm.sup.-1, 729.9.+-.0.1 cm.sup.-1, 694.3.+-.0.1 cm.sup.-1 630.6.+-.0.1 cm.sup.-1, 603.6.+-.0.1 cm.sup.-1, 556.4.+-.0.1 cm.sup.-1, 501.4.+-.0.1 cm.sup.-1 and 443.6.+-.0.1 cm.sup.-1 in an infrared absorption spectrum (KBr method).

19. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 5.7.degree., 9.5.degree., 23.7.degree. and 25.0.degree. in a powder X-ray diffraction.

20. An anhydrous crystal of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one having a diffraction peak at a diffraction angle (2.theta..+-.0.2.degree.) of 5.7.degree., 7.7.degree., 8.7.degree., 9.5.degree., 11.6.degree., 12.4.degree., 17.6.degree., 23.7.degree. and 25.0.degree. in a powder X-ray diffraction.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc